Lilly Open To Providing More Guidance On Duration Of Treatment With Evista
Executive Summary
The length of time that women take Lilly's Evista to decrease risk of invasive breast cancer is a decision to be made by patients and physicians, the company contended during a July 24 meeting of FDA's Oncologic Drugs Advisory Committee
You may also be interested in...
Eli Lilly's Oncology Focus
On October 6, Eli Lilly & Co. became the latest pharmaceutical company to jump on the cancer bandwagon, with its $6.5 billion acquisition of ImClone Systems Inc.The deal gives Lilly the royalty stream to one marketed product-cetuximab (Erbitux), plus five additional clinical stage compounds, many of which are biologics. The problem is many of the candidate drugs face stiff competition--and the pharma has severely depleted its cash holdings to get the deal signed.
Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning
FDA's approval of Lilly's osteoporosis drug Evista for two preventative cancer treatment indications expands the drug's market into the oncology field, while placing it at odds with competing osteoporosis products because of new risk labeling
Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning
FDA's approval of Lilly's osteoporosis drug Evista for two preventative cancer treatment indications expands the drug's market into the oncology field, while placing it at odds with competing osteoporosis products because of new risk labeling